American Association for Cancer Research
00085472can172316-sup-187170_3_supp_4611006_p56psm.pdf (229.13 kB)

Figure S8 from Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis

Download (229.13 kB)
journal contribution
posted on 2023-03-31, 01:24 authored by Priyanka Singh, Laura M. Jenkins, Ben Horst, Victoria Alers, Shrikant Pradhan, Prabhjot Kaur, Tapasya Srivastava, Nadine Hempel, Balázs Győrffy, Eugenia V. Broude, Nam Y. Lee, Karthikeyan Mythreye

: Representative western blot of lysates from 6 hr serum starved HMEC-1 cells incubated with 10ng/ml Activin up to 40 min, followed by immunoblotting of lysates as indicated. Quantitation from two independent biological trials is presented (right graphs).





Inhibin is a heterodimeric TGFβ family ligand that is expressed in many cancers and is a selective biomarker for ovarian cancers; however, its tumor-specific functions remain unknown. Here, we demonstrate that the α subunit of inhibin (INHA), which is critical for the functionality of dimeric inhibin A/B, correlates with microvessel density in human ovarian tissues and is predictive of poor clinical outcomes in multiple cancers. We demonstrate that inhibin-regulated angiogenesis is necessary for metastasis. Although inhibin had no direct impact on tumor cell signaling, both tumor cell-derived and recombinant inhibin elicit a strong paracrine response from endothelial cells by triggering SMAD1/5 activation and angiogenesis in vitro and in vivo. Inhibin-induced angiogenesis was abrogated via anti-inhibin α antibodies. The endothelial-specific TGFβ receptor complex comprising ALK1 and endoglin was a crucial mediator of inhibin signaling, offering a molecular mechanism for inhibin-mediated angiogenesis. These results are the first to define a role for inhibin in tumor metastasis and vascularization and offer an antibody-based approach for targeting inhibin therapeutically.Significance: Inhibin is a predictor of poor patient survival in multiple cancers and is a potential target for antiangiogenic therapies. Cancer Res; 78(11); 2978–89. ©2018 AACR.